Regeneron Pharmaceuticals (REGN) reported strong financial results for Q4 2024, with a 10% year-over-year revenue growth, reaching $3.8 billion. Key drivers included its blockbuster drugs Dupixent, which brought in $3.7 billion globally, Libtayo, which exceeded expectations with $367 million in sales, and the eye drug EYLEA, which posted U.S. sales of $1.5 billion, despite ongoing competitive pressure from biosimilars. The company also made a notable move by initiating a quarterly dividend of $0.88 per share, or $3.52 annually, signaling confidence in its cash flow. For 2024, Regeneron reported a net income of $1.4 billion and free cash flow of approximately $3.7 billion. The company also guided for higher operating expenses in 2025 due to its expanding pipeline, which includes promising candidates like Linvoseltamab and Odronextamab. However, concerns remain around the future of EYLEA as biosimilars continue to challenge its market share. Regeneron also faces risks related to the safety profile of some of its pipeline products, particularly in the complement programs. Despite these challenges, analysts remain optimistic, citing the company’s solid pipeline, growing product sales, and strategic focus on shareholder returns through dividends and stock buybacks. Our proprietary model rates this stock as a Buy, with 10-15% growth from here. Today's REGN closed at $666.85.

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion Please visit their website for more information.

Our proprietary analysis employs a weighted average approach integrating both functional and technical parameters, tailored to the sector, industry, and microeconomic factors. This methodology assigns dynamic weights to the parameters, with a focus on recent trends, ensuring a nuanced evaluation for informed investment decisions. Considering various financial parameters of the stock from its income statement, balance sheet, and cash flow, in addition to some of the derived parameters of the stock in conjunction with its sector and macroeconomic conditions, our proprietary Weighted Average AI model gives a rank of Buy.

TheoryofStocks is not registered as an investment advisor with any regulatory authority. The information provided on this Website is for educational purposes only and should not be construed as financial or investment advice. By continuing to use this site, you are agreeing to the Terms of Use and Privacy Policy. Please read our Disclaimer.

Contact @ support@theoryofstocks.com

© 2024 Stock Articles. All rights reserved.